Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_218_библиотеки_им_акад_М_И_Перельмана
.pdf
151
Список литературы
198. Gulsvik A.K., A. Gulsvik A, Skovlund E. et al. e association between lung function
and fatal stroke in a community followed for 4 decades // J. Epidemiol. Community
Health. 2012. Vol. 66, № 1. P. 1030–1036.
199.
Guo X., M.J. Oldham, M.T. Kleinman et al. Eect of cigarette smoking on nitric
oxide, structural, and mechanical properties of mouse arteries // Am. J. Physiol.
Heart Circ. Physiol. 2006. Vol. 291, N.5. Р. 2354 –2361.
200.
Guo Y., Zhang T., Wang Z. et al. Body mass index and mortality in COPD: A
dose response meta-analysis // Medicine (Baltimor). 2016. Vol. 95, N. 28. E. 4225.
201.
Habib G.M., Rabinovich R., Divgi K. et al. Systematic review (protocol) of clinical
eectiveness and models of care of low-resource pulmonary rehabilitation // NPJ
Prim Care Respir Med. 2019. Vol. 29. P. 10.
202. Hajifathalian K., Ueda P., Lu Y. et al. A novel risk score to predict cardiovascular
disease risk in national populations (Globorisk): a pooled analysis of prospective
cohorts and health examination surveys // Lancet Diabetes Endocrinol. 2015. Vol.
3. № 5. Р. 339-355.
203. Hansson G.K., Jörnvall H., Lindahl S.G. e Nobel Prize 1998 in physiology or
medicine. Nitrogen oxide as a signal molecule in the cardiovascular system //
UgeskrLaeger. 1998. Vol. 160. N. 52. P. 7571-7578.
204. Hartmann G., Tschop M., Fischer R. et al. High altitude increases circulating
interleukin-6, interleukin-1 receptor antagonist and C-reactive protein // Cytokine.
2000. Vol. 12, № 3. P. 246–252.
205. Harvey A., Montezano A.C., Touyz R.M. Vascular biology of ageing– Implications
in hypertension // J Mol Cell Cardiol. 2015. № 83. Р. 112-121.
206. Heeschen C., Weis M., Cooke J.P. Nicotine promotes arteriogenesis // J Am
CollCardiol. 2003. Vol. 41. P. 489–496.
207.
Henning B., Diana J. N., Toborek M. et. al. Inuence of nutrients and cytokines
on endothelial cell metabolism // J Am Coll Nutr. 1994. Vol. 13, № 3. P. 224–231.
208. Hill K., Goldstein R.S., Guyatt G.H. et al. Prevalence and underdiagnosis of chronic
obstructive pulmonary diseaseamong patients at risk in primary care // CMAJ.
2010. Vol. 182, N. 7. P. 673–678.
209. Hippisley-Cox J., Coupland C., Vinogradova Y. et al. Derivation and validation of
QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective
open cohort study // BMJ. 2007. Vol. 335. № 7611. Р. 136.
210. Holguin F., Folch E., Redd S.C. et al. Comorbidity and mortality in COPD-
related hospitalizations in the United States, 1979 to 2001 // Chest. 2005. Vol. 128.
P. 2005–2011.
211. Houchen-Wollo L., Steiner M.C. Pulmonary rehabilitation at a time of social
distancing: prime time for tele-rehabilitation? // orax. 2020. Vol. 75, N. 6. P. 446-447.
https://t.me/med1917
152
Список литературы
212. Hozawa A., Billings J.L., Shahar E. et al. Lung function and ischemic stroke
incidence: the atherosclerosis risk in communities study // Chest. 2006. Vol. 130,
№ 6. P. 1642–1649.
213.
Hunninghake D.B. Cardiovascular disease in chronic obstructive pulmonary
disease // Proc. Am. orac. Soc. 2005. № 2 (1). Р. 44– 49.
214.
Illyes M. A new and fast screening method for complex hemodynamical parameters
and arterial stiness noninvasively with a simple arm cu TensioMed Ltd, Budapest,
Hungary // American Journal of Hypertension. 2005. Vol. 18, N. 5(2). P.17.
215. Israili Z.H., Hall W.D. Cough and angioneurotic edema associated with
angiotensin-converting enzyme inhibitor therapy. A review of the literature and
pathophysiology // Ann Intern Med. 1992. Vol. 117, N. 3. P. 234–242.
216. Janson C., Larsson K., Lisspers K.H. et al. Pneumonia and pneumonia related
mortality in patients with COPD treated with xed combinations of inhaled
corticosteroids and long acting b2 agonist: observational matched cohort study
(PATHOS) // Br Med J. 2013. Vol. 346. f3306.
217. Johansen N.B., Vistisen D., Brunner E.J. et al. Determinants of aortic stiness:
16-year follow-up of the Whitehall II study // PLoS One. 2012. Vol. 7. № 5. Р. e37165.
218.
Jones P.W., Rennard S.I, Agusti A .et al. Ecacy and safety of once-daily aclidinium
in chronic obstructive pulmonary disease // Respir Res. 2011. Vol. 12. P. 55.
219.
Kaisar M.A., Prasad S., Cucullo L. Protecting the BBB endothelium against
cigarette smoke-induced oxidative stress using popular antioxidants: are they really
benecial? // Brain Res. 2015. Vol. 1627. P. 90–100.
220.
Kanazawa H., Hirata K., Yoshikawa J. Eects of captopril administration on
pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene
subtypes in patients with COPD: a preliminary study // orax. 2003. Vol. 58, 7.
P. 629–631.
221. Kang M.J., Oh Y.M., Lee J.C. et al. Lung matrix metalloproteinase-9 correlates with
cigarette smoking and obstruction of airow // J. Korean Med. Sci. 2003. Vol. 18,
№ 6. P. 821–827.
222. Kang M.J., Yoon C.M., Kim B.H. et al. Suppression of NLRX1 in chronic obstructive
pulmonary disease // J Clin Invest. 2015. N. 125. P. 2458–2462.
223. Karner C., Cates C.J. Long-acting beta2-agonist in addition to tiotropium versus
either tiotropium or long-acting beta2-agonist alone for chronic obstructive
pulmonary disease // Cochrane Database Syst Rev. 2012. 4: CD008989.
224. Karner C., Chong J., Poole P. Tiotropium versus placebo for chronic obstructive
pulmonary disease // Cochrane Database Syst Rev. 2012. Vol. 7. CD009285.
225. Kasahara Y., Tuder R. M., Taraseviciene-Stewart L. et al. Inhibition of VEGF
receptors causes lung cell apoptosis and emphysema // J. Clin. Invest. 2000. Vol. 106,
№ 11. P. 1311–1319.
https://t.me/med1917
153
Список литературы
226. Katz D.A., Muehlenbruch D.R., Brown R.L. et al. Eectiveness of implementing
the agency for healthcare research and quality smoking cessation clinical practice
guideline: a randomized, controlled trial // J Natl Cancer Inst. 2004. Vol. 96, N. 8.
P. 594–603.
227.
Kayyali U. S., Budhiraja R., Pennella C. M. et al. Upregulation of xanthine oxidase
by tobacco smoke condensate in pulmonary endothelial cells // Toxicol. Appl.
Pharmacol. 2003. Vol. 188, № 1. P. 59–68.
228. Kazmierczak M., Ciebiada M., Pekala-Wojciechowska A. et al. Evaluation of
markers of inammation and oxidative stress in COPD patients with or without
cardiovascular comorbidities // Heart Lung Circ. 2015. Vol. 24, № 8. P. 817–823.
229. Kew K.M., Mavergames C., Walters J.A. Long-acting beta2-agonists for chronic
obstructive pulmonary disease // Cochrane Database Syst Rev. 2013. Vol. 15, N. 10.
230.
Kew K.M., Seniukovich A. Inhaled steroids and risk of pneumonia for chronic
obstructive pulmonary disease // Cochrane Database Syst Rev. 2014. N. 3.
CD010115.
231. Khuseyinova N., Muller P., Schulz A. et al. Age- and gender-specic distribution
of arterial stiness in the population and its association with global cardiovascular
risk: results from the population-based Gutenberg Health study // Eur. Heart. J.
2012. № 33(suppl 1). Р. 949.
232. Kirchhof P., Benussi S., Kotecha D. et al. Рекомендации ESC по лечению пациен-
тов с фибрилляцией предсердий, разработанные совместно с EACTS // Рос-
сийский кардиологический журнал. 2017. № 7. С. 7-86.
233.
Kirkham P. A., Barnes P. J. Oxidative stress in COPD // Chest. 2013. Vol. 144, № 1.
P. 266–273.
234. Kirkpatrick C.J., Bittinger F., UngeR.E. et al.e non-neuronal cholinergic system
in the endothelium: evidence and possible pathobiological signicance // Jpn J
Pharmacol. 2001. Vol. 85. P. 24–28.
235. Kirsti H.P. Genotoxicity of environmental tobacco smoke: a review // Mutat. Res.
2004. Vol. 567, № 2. P. 427–445.
236. Koch A., Pizzichini E., Hamilton A. et al. Lung function ecacy and symptomatic
benet of olodaterol once daily delivered via Respimat versus placebo and
formoterol twice daily in patients with GOLD 2-4 COPD: results from two
replicate 48-week studies // Int J Chron Obstruct Pulmon Dis. 2014. Vol. 9.
P. 697–714.
237. Kuller L.H., Longstreth W.T., Arnold A.M. et al. Cardiovascular Health Study
Collaborative Research Group. White matter hyperintensity on cranial magnetic
resonance imaging: a predictor of stroke // Stroke. 2004. Vol. 35, № 8. P. 1821–1825.
238. Kurth T., Kase C.S., Berger K. et al. Smoking and risk of hemorrhagic stroke in
women // Stroke. 2003. Vol. 34, № 12. P. 2792–2795.
https://t.me/med1917
154
Список литературы
239. Kwiatkowska S., Noweta K., Zieba M. et al. Enhanced exhalation of matrix
metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients
with COPD exacerbation: a prospective study // Respiration. 2012. Vol. 84, № 3.
P. 231–241.
240.
Lacolley P., Regnault V., Nicoletti A. et al. e vascular smooth muscle cell in
arterial pathology: a cell that can take on multiple roles // Cardiovasc Res. 2012.
Vol. 95. P. 194–204.
241. Lahousse L., Niemeijer M.N., van den Berg ME et al. Chronic obstructive pulmonary
disease and sudden cardiac death: the Rotterdam study // Eur Heart J. 2015. Vol. 36,
N. 27. P.1754–1761.
242. Lannert A. e importance of arterial stiness measurement. TensioMed
Arteriograph. Hungarian Arterial Stiness Society. Budapest. 2007. 32p.
243.
Lareau S.C., Fahy B. Pulmonary Rehabilitation. Am oracic Society Patient
Education Series // Am J Respir Crit Care Med. 2018. Vol. 198. P. 19–20.
244.
Lattimore J. D., Wilcox I., Nakhla S. et al. Repetitive hypoxia increases lipid loading
in human macrophages-a potentially atherogenic eect // Atherosclerosis. 2005.
Vol. 179, № 2. P. 255–259.
245. Layden J.E., Ghinai I., Pray I. et al. Pulmonary Illness Related to E-Cigarette Use in
Illinois and Wisconsin. Preliminary Report // N Engl J Med. 2020. Vol. 382, N. 10.
P. 903–916.
246. Leitzmann M.F., Park Y., Blair A. et al. Physical activity recommendations and
decreased risk of mortality // Arch Intern Med. 2007. Vol. 167. P. 2453–2460.
247. Lenferink A., Brusse-Keizer M., van der Valk P.D. et al. Self-management
interventions including action plans for exacerbations versus usual care in patients
with chronic obstructive pulmonary disease // Cochrane Database Syst Rev. 2017.
Vol. 8. CD011682.
248. Light R.W., Chetty K.G., Stansbury D.W. Comparison of the eects of labetalol
and hydrochlorothiazide on the ventilatory function of hypertensive patients with
mild chronic obstructive pulmonary disease // Am J Med. 1983. Vol. 75, N 4A.
P. 109–114.
249. Lim S., Roche N., Oliver B.G. et al. Balance of matrix metalloprotease-9 and tissue
inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers.
Regulation by interleukin-10 // Am. J. Respir. Crit. Care Med. 2000. Vol. 162, № 4,
Pt. 1. P. 1355–1360.
250. Lim S.S., Vos T., Flaxman A.D. et al. A comparative risk assessment of burden
of disease and injury attributable to 67 risk factors and risk factor clusters in 21
regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study
2010 // Lancet. 2012. Vol. 380. P. 2224–2260.
https://t.me/med1917
155
Список литературы
251. Lipson D.A., Barnhart F., Brealey N. et al. Once-Daily Single-Inhaler Triple versus
Dual erapy in Patients with COPD // NEJM. 2018. Vol. 378. P. 1671-1680.
252.
Lipworth B.J., McDevitt D.G., Struthers A.D. Prior treatment with diuretic augments
the hypokalemic and electrocardiographic eects of inhaled albuterol // Am J Med.
1989. Vol. 86, N. 6. Pt 1. P. 653–657.
253. Liu X., Xie C. Human endothelial progenitor cells isolated from COPD patients are
dysfunctional // Mol. Cell Biochem. 2012. Vol. 363, № 1-2. P. 53–63.
254.
Loke Y.K., Cavallazzi R., Singh S. Risk of fractures with inhaled corticosteroids in
COPD: systematic review and meta-analysis of randomised controlled trials and
observational studies // orax. 2011. Vol. 66. P. 699–708.
255. Lopez-Sanchez M., Munoz-Esquerre M., Huertas D. et al. High Prevalence of Le
Ventricle Diastolic Dysfunction in Severe COPD Associated with A Low Exercise
Capacity: A Cross-Sectional Study // PLoS One. 2013. Vol. 8, N 6. e68034.
256. Maclay J.D., MacNee W. Cardiovascular disease in COPD: mechanisms // Chest.
2013. Vol. 143, N. 3. P.798–807.
257.
Mahmud A., Feely J. Eect of Smoking on Arterial Stiness and Pulse Pressure //
Amplication Hypertension. 2003. Vol. 41. P.183-187.
258.
Maltais F., Bourbeau J., Shapiro S. et al. Eects of home-based pulmonary
rehabilitation in patients with chronic obstructive pulmonary disease: a randomized
trial // Ann Intern Med. 2008. Vol. 149, N. 12. P.869–878.
259. Maltais F., Ostinelli J., Bourbeau J. et al. Comparison of nebulized budesonide and
oral prednisolone with placebo in the treatment of acute exacerbation of chronic
obstructive pulmonary disease: a randomized controlled trial // Am J Respir Crit
Care Med. 2002. Vol. 165, N. 5. P.698–703.
260. Man W.D.C., Kemp P., Moxham J. et al. Polkey MI. Skeletal muscle dysfunction
in COPD: clinical and laboratory observations // Clin Sci (Lond). 2009. Vol. 117.
P. 251–264.
261. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC guidelines for the
management of arterial hypertension: the Task Force for the Management of
Arterial Hypertension of the ESH and ESC // Eur Heart J. 2013. Vol. 34. P. 2159–
2219.
262. Mancini G.B., Etminan M., Zhang B. et al. Reduction of morbidity and mortality
by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor
blockers in patients with chronic obstructive pulmonary disease // J Am Coll
Cardiol. 2006. Vol. 47, N. 12. P. 2554–2560.
263. McManus R.J., Mant J., Bray E.P. et al. Telemonitoring and self-management in
the control of hypertension (TASMINH2): a randomised controlled trial // Lancet.
2010. Vol. 376. P.163–172.
https://t.me/med1917
156
Список литературы
264. Mayhan W.G., Arrick D.M., Sharpe G.M. et al. Age-related alterations in reactivity
of cerebral arterioles: role of oxidative stress // Microcirculation. 2008. Vol. 15,
№ 3. P. 225–236.
265.
Mehra M.R., Desai S.S., Kuy S. et al. Cardiovascular Disease, Drug erapy, and
Mortality in Covid-19 // N Engl J Med. 2020. Epub 2020/05/02.
266.
Mercer P.F., Shute J.K., Bhowmik A. et al. MMP-9, TIMP-1 and inammatory cells
in sputum from COPD patients during exacerbation // Respir. Res. 2005. Vol. 6,
№ 1. P. 151.
267. McGuinness A. J., Sapey E. Oxidative stress in COPD: sources, markers, and
potential mechanisms // J Clin Med. 2017. Vol. 6, № 2. P. 21.
268.
Miller J., Edwards L.D., Aguste A. et al. Comorbidity, systemic inammation and
outcomes in the ECLIPSE cohort // Respir Med. 2013. Vol. 107, N 9. P. 1376-1384.
269.
Mills N.L., Miller J.J., Anand A. et al. Increased arterial stiness in patients with
chronic obstructive pulmonary disease: a mechanism for increased cardiovascular
risk // orax. 2008. Vol. 63, № 4. P. 306–311.
270. Minet C., Vivodtzev I., Tamisier R. et al. Reduced six-minute walking distance, high
fat-free-mass index and hypercapnia are associated with endothelial dysfunction in
COPD // Respir Physiol Neurobiol. 2012. Vol. 183, № 2. P. 128–134.
271. Miravitlles M., Espinosa C., Fernandez-Laso E. et al. Relationship between bacterial
ora in sputum and functional impairment in patients with acute exacerbations of
COPD. Study Group of Bacterial Infection in COPD // Chest. 1999. Vol. 116, N. 1.
P. 40–46.
272. Miravitlles M., Kruesmann F., Haverstock D. et al. Sputum colour and bacteria in
chronic bronchitis exacerbations: a pooled analysis // Eur Respir J. 2012. Vol. 39,
N. 6. P.1354–1360.
273. Moore R.P., Berlowitz D.J., Denehy L. et al. A randomized trial of domiciliary,
ambulatory oxygen tin patients with COPD and dyspnea but without resting
hypoxaemia // orax. 2011. Vol. 66. P. 32–37.
274.
Mortensen E.M., Copeland L.A., Pugh M.J.V. et al. Impact of statins and ACE
inhibitors on mortality aer COPD exacerbations // Respir Res. 2009. Vol. 10. P. 45.
275.
Mortensen M.B., Falk E. Limitations of the SCORE-guided European guidelines on
cardiovascular disease prevention // European Heart Journal. 2017. Vol. 38. № 29.
Р. 2259-2263.
276. Muijsers R. B. R, Folkets G., Henricks P. A. J. et al. Peroxynitrite: a two-fased
metabolite of nitric oxide // Life Sci. 1997. Vol. 60, № 21. P. 1833–1845.
277. Mulvany M.J. Small artery structure: time to take note? // Am J Hypertens. 2007.
Vol. 20. № 8. Р. 853-854.
278. Mulvany M.J. Structural abnormalities of the resistance vasculature in
hypertension // J Vasc Res. 2003. Vol. 40. № 6. Р. 558-560.
https://t.me/med1917
157
Список литературы
279. Mulvany M.J. Vascular remodelling of resistance vessels: can we dene this? //
Cardiovasc Res. 1999. Vol. 41. № 1. Р. 9-13.
280.
Muthusami R., Mahmoud M., Crawford E. et al. Assessment of chronic obstructive
airways disease in heart failure: An analysis of current practice // Am J Respiratory
Crit Care Med. Vol. 2018. 197:1244.
281. Nadruz W. Jr., Goncalves A., Claggett B. et al. Inuence of cigarette smoking on
cardiac biomarkers: the Atherosclerosis Risk in Communities (ARIC) Study // Eur.
J. Heart Fail. 2016. Vol. 18, № 6. P. 629–637.
282. Naik V., Leaf E.M., Hu J.H. et al. Sources of cells that contribute to atherosclerotic
intimal calcication: an in vivo genetic fate mapping study // Cardiovasc Res. 2012.
Vol. 94. P. 545–554.
283. Nevzorova V.A., Brodskaya T.A., Barchatova D.A. Сytokines, extracellular matrix
metalloproteinases and arterial stiness in // European Respiratory Journal. 2008.
Т. 32. № S52. С. 589.
284. Nevzorova V., Brodskaya T., Gilifanov E. Smoking and COPD: endothelium-related
and neuro-mediated emphysema mechanisms. In book: Update in Respiratory
Diseases. London, 2020.
285. Nevzorova V., Brodskaya T., Zakharchuk N. Smocking, Respiratory diseases and
Endothelial dysfunction. In: Endothelial Dysfunction– Old Concepts and New
Challenges. Edited by Helena Lenasi. London. IntechOpen, 2018. P. 307-325.
286. Nevzorova V., Zaharchuk N., Gonchar E. et al. Cerebral vascular reactivity in
duplex scanning in patients with COPD // European Respiratory Journal. 2013.
Vol. 42. Suppl. 57. P. 418.
287.
Ni Y., Shi G., Wan H. Use of Cardioselective b-Blockers in Patients with Chronic
Obstructive Pulmonary Disease: A Meta-Analysis of Randomized, Placebo-
controlled, Blinded Trials // J Int Med Res. 2012. Vol. 40, N. 6. P. 2051–2065.
288. Nouira S., Marghli S., Belghith M. et al. Once daily oral ooxacin in chronic
obstructive pulmonary disease exacerbation requiring mechanical ventilation: a
randomised placebo-controlled trial // Lancet. 2001. Vol. 358, N. 9298. P. 2020–2025.
289. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital
surveillances: the epidemiological characteristics of an outbreak of 2019 novel
coronavirus diseases (COVID-19)– China // China CDC Weekly. 2020. Vol. 2,
N. 8. P. 113-122.
290. Oelsner E. C., Pottinger T. D., Burkart K. M. et al. Adhesion molecules, endothelin-1
and lung function in seven population-based cohorts // Biomarkers. 2013. Vol. 18,
№ 3. P. 196–203.
291. Oren A., Vos L.E., Uiterwaal C.S. et al. // Aortic stiness and carotid intimal-media
thickness: two independent markers of subclinical vascular damage in young
adults? // Eur. J. Clin. Invest. 2003. Vol. 33, № 11. P. 949–954.
https://t.me/med1917
158
Список литературы
292. Owens G.K. Regulation of dierentiation of vascular smooth muscle cells // Physiol
Rev. 1995. V. 75. P. 487–517.
293.
Palange P., Testa U., Huertas A. et al. Circulating haemopoietic and endothelial
progenitor cells are decreased in COPD // Eur Respir J. 2006. Vol. 27, № 3.
P. 529–541.
294. Pant R., Marok R., Klein L.W. Pathophysiology of coronary vascular remodeling:
relationship with traditional risk factors for coronary artery disease // Cardiol Rev.
2014. Vol. 22. № 1. Р. 13-16.
295. Papakonstantinou E., Kara-kiulakis G., Batzios S. et al. Acute exacerbations of
COPD are associated with signicant activation of matrix metalloproteinase 9
irrespectively of airway obstruction, emphysema and infection // Respir Res. 2015.
Vol. 16, № 1. P. 78.
296. Park L., Anrather J., Girouard H. et al. Nox2-derived reactive oxygen species
mediate neurovascular dysregulation in the aging mouse brain // J. Cereb. Blood
Flow Metab. 2007. Vol. 27, № 12. P. 1908–1918.
297. Раuса A.L., Kon N.D., O’Rourke M.F. Benet of glyceryl trinitrate on arterial stiness
is directly due to eects on peripheral arteries // Heart. 2005. № 91. P.1428-1432.
298.
Pelkonen M., Notkola I.L., Tukiainen H. et al. Smoking cessation, decline in
pulmonary function and total mortality: a 30-year follow-up study among the
Finnish cohorts of the Seven Countries Study // orax. 2001. Vol. 56. P.703–707.
299. Peinado V.I., Barbera J.A., Ramirez J. et al. Endothelial dysfunction in pulmonary
arteries of patients with mild COPD // Am. J. Physiol. 1998. Vol. 274, № 6, Pt. 1.
P. L908–L913.
300.
Phelan D., Collier P., avendiranathan P. et al. Relative apical sparing of
longitudinal strain using two-dimensional speckle-tracking echocardiography is
both sensitive and specic for the diagnosis of cardiac amyloidosis // Heart. 2012.
N. 98. P.1442–1448.
301.
Piepoli M.F., Hoes A.W., Agewall S. et al. 2016 European Guidelines on
cardiovascular disease prevention in clinical practice // Eur Heart J. 2016. Vol. 37.
№ 29. Р. 2315-2381.
302. Polosa R., Malerba M., Cacciola R. R. et al. Eect of acute exacerbations on
circulating endothelial, clotting and brinolytic markers in COPD patients // Intern
Emerg Med. 2013. Vol. 8, № 7. P.567–574.
303. Polverino F., Celli B.R., Owen C.A. COPD as an endothelial disorder: endothelial
injury linking lesions in the lungs and other organs? (2017 Grover Conference
Series) // Pulmonary Circulation. 2018. Vol. 8(1):2045894018758528.
304. Ponikowski P., Voors A., Anker S. et al. Рекомендации ESC по диагностике иле-
чению острой ихронической сердечной недостаточности. 2016 // Российский
кардиологический журнал. 2017. № 1. С. 7-81.
https://t.me/med1917
159
Список литературы
305. Poole P., Black P.N., Cates C.J. Mucolytic agents for chronic bronchitis or chronic
obstructive pulmonary disease // Cochrane Database Syst Rev. 2012. Vol. 8:
CD001287.
306.
Poole P.J., Chacko E., Wood-Baker R.W., Cates C.J. Inuenza vaccine for patients
with chronic obstructive pulmonary disease // Cochrane Database Syst Rev. 2006.
Vol. 1. CD002733.
307.
Portegies M.L., Lahousse L., Joos G.F. et al. Chronic Obstructive Pulmonary Disease
and the Risk of Stroke. e Rotterdam Study // Am J Respir Crit Care Med. 2016.
Vol. 193, N. 3. P.251-258.
308. Puente-Maestu L., Palange P., Casaburi R. et al. Use of exercise testing in the
evaluation of interventional ecacy: an ocial ERS statement // Eur Respir J. 2016.
Vol. 47, N. 2. P. 429–460.
309. Puhan M.A., Busching G., Schunemann H.J. et al. Interval versus continuous high-
intensity exercise in chronic obstructive pulmonary disease: a randomized trial //
Ann Intern Med. 2006. Vol. 145. P. 816–825.
310. Puhan M.A., Gimeno-Santos E., Scharplatz M. et al. Pulmonary rehabilitation
following exacerbations of chronic obstructive pulmonary disease // Cochrane
Database Syst Rev. 2011. Vol. 10. CD005305.
311. Puranik R., Celermajer D.S. Smoking and endothelial function //Prog Cardiovasc
Dis. 2003. Vol. 4. P. 443–458.
312.
Rabahi M.F., Pereira S.A., Silva Júnior J.L. et al. Prevalence of chronic obstructive
pulmonary disease among patients with systemic arterial hypertension without
respiratory symptoms // Int J Chron Obstruct Pulmon Dis. 2015. Vol. 10.
P. 1525–1529.
313. Rabkin-Aikawa E., Aikawa M., Kratz J.R. et al. Clinical pulmonary autogra
valves: pathologic evidence for adaptive remodeling in the aortic site // J. orac.
Cardiovasc. Surg. 2004. Vol. 128, № 4. P. 552–561.
314. Rahman I. Pharmacological antioxidant strategies as therapeutic interventions for
COPD // Biochim Biophys Acta. 2012. Vol. 1822, № 5. P. 714–728.
315. Ramirez-Venegas A., Ward J., Lentine T. et al. Salmeterol reduces dyspnea
and improves lung function in patients with COPD // Chest. 1997. Vol. 112, 2.
P. 336–340.
316. Reinikovaite V., Rodriguez I.E., Karoor V. et al. e eects of electronic cigarette
vapour on the lung: direct comparison to tobacco smoke // Eur Respir J. 2018.
Vol. 51(4):1701661.
317. Renna N.F., De las Heras N., Miatello R.M. Pathophysiology of Vascular Remodeling
in Hypertension // Int J Hypertens. 2013. № 2013. Р. 808353.
318. Repine J. E., Bast A., Lankhorst I. Oxidative stress in chronic obstructive pulmonary
disease // Am J Respir Crit Care Med. 1997. Vol. 156, № 2, Pt. 1. P. 341–357.
https://t.me/med1917
160
Список литературы
319. Ries A.L., Bauldo G.S., Carlin B.W. et al. Pulmonary Rehabilitation: Joint ACCP/
AACVPR Evidence-Based Clinical Practice Guidelines // Chest. 2007. Vol. 131.
P. 4–42.
320.
Riise G. C., Larsson S., Lofdahl C. G. et al. Circulating cell adhesion molecules in
bronchial lavage and serum in COPD patients with chronic bronchitis // Eur. Respir.
J. 1994. Vol. 7, № 9. P. 1673–1677.
321.
Rogliani P., Matera M.G., Ora J. et al. e impact of dual bronchodilation on
cardiovascular serious adverse events and mortality in COPD: a quantitative
synthesis // Int J Chron Obstruct Pulmon Dis. 2017. Vol. 12. P. 3469–3485.
322. Rongen G.A., Smits P., ien T. Endothelium and the regulation of vascular tone
with emphasis on the role of nitric oxide. Physiology, pathophysiology and clinical
implications // Neth J Med. 1994 . Vol. 44. N. 1. P. 63–65.
323. Ross R. e pathogenesis of arteriosclerosis: a perspective for the 1990s //Nature.
1993. Vol. 362. P. 801-809.
324.
Rossi A., Dikareva A., Bacon S.L. et al. e impact of physical activity on mortality
in patients with high blood pressure: a systematic review // J Hypertens. 2012.
Vol. 30. P. 1277–1288.
325. o’Rourke M. F., Hashimoto J. Mechanical factors in arterial aging: a clinical
perspective // J. Am. Coll. Cardiol. 2007. Vol. 50, № 1. P. 1–13.
326.
Sabit R., Bolton C.E., Edwards P.H. et al. Arterial stiness and osteoporosis in
chronic obstructive pulmonary disease // Am. J. Respir. Crit. Care Med. 2007.
Vol. 175. P. 1259–1265.
327.
Salame J., Scott J.E. Modulation of matrix metalloproteinase activity by tobacco
cigarette smoke // Cur. Chem. Biol. 2016. Vol. 3, № 3. P. 315–323.
328. Salpeter S., Ormiston T., Salpeter E. Cardioselective beta-blockers for chronic
obstructive pulmonary disease // Cochrane Database Syst Rev. 2005. Vol. 4.
CD003566.
329. Salpeter S.R., Ormiston T.M., Salpeter E.E. Cardiovascular eects of b-agonists
in patients with asthma and COPD: A meta-analysis // Chest. 2004. Vol. 125.
P. 2309–2321.
330. Salpeter S.R., Ormiston T.M., Salpeter E.E. Cardioselective beta-blockers in patients
with reactive airway disease: a meta-analysis // Ann Intern Med. 2002. Vol. 137, 9.
P. 715–725.
331. Savransky V., Nanayakkara A., Li J. et al. Chronic intermittent hypoxia induces
atherosclerosis // Am J Respir Crit Care Med. 2007. Vol. 175, № 12. P. 1290–1297.
332. Schaeer T., B eerbaum P., Gaddum N. et al. Aortic pulse wave velocity measurement.
Patent GBWO/2013/110929. International Application No PCT/GB2013/050131.
Publication Date 01.08.2013.
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана